and biomedical discovery
Spin-offs are business initiatives promoted by IDIS researchers created to develop new processes, products or services based on knowledge or technologies resulting from IDIS’s research activity.
Creating spin-offs offers many advantages to the different stakeholders involved:
- Researchers/entrepreneurs may continue developing technology generated at IDIS until they turn it into a final product, attract financing to develop their project and obtain yields from this process.
- IDIS promotes the application of research results to society by means of the creation of products and services which meet the required needs, and it may obtain yields from the licensing of technologies which are afterwards used for the financing of new researches.
- Thus, our society benefits from services and products which meet their health care needs, as well as from qualified jobs generated by spin-offs and from the taxes they pay.
Biotechnology company which develops clinical solutions to improve cancer diagnosis, prognosis and treatment. Incorporated in 2014 as a result of a research project in biomedicine developed at the Translational Medical Oncology Laboratory of the Health Research Institute (IDIS) of Santiago de Compostela.
Detection And Radiation Technologies, S.L.
This company was established with the purpose of developing advanced solutions for dosimetry verification, with quality control applications in Medical Imaging, and for the measurement of radiotherapy doses administered to a patient. DART was created in 2014 as a result of the liquid ionization chamber technology developed by the Research Group in Colloid and Polymer Physics of the Health Research Institute (IDIS) of Santiago de Compostela and the Research Group in Radiophysics Research of the University of Santiago.
Qubiotech, Health Intelligence, S.L.
Company specializing in the development and marketing of software for the advanced processing of medical imaging. Qubio was established in December 2014 as a result of the transfer of an algorithm for imaging quantification by Positron Emission Tomography (PET) developed by the Research Group in Nuclear Medicine and Molecular Imaging of the Health Research Institute (IDIS) of Santiago de Compostela.
Company specialized in the development of innovative solutions for an improved management of patients suffering from highly prevalent neurological diseases such as brain haemorrhage and Alzheimer’s disease. It was incorporated in 2017 as a result of an algorithm developed by the Research Group in Clinical Neuroscience (LINC) of the Health Research Institute (IDIS) of Santiago de Compostela.